Why Longevita Uses NR + Nicotinamide for Daily NAD+ Support

Most NAD+ supplements make a single bet. They pick one precursor, usually nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), build the entire formula around it, and market that ingredient as the whole story. It's a simple pitch, and it sells. But it's also a narrower approach than the biology actually calls for.

NAD+ decline isn't a single-pathway problem. It touches mitochondrial energy production, DNA repair, epigenetic regulation, antioxidant defence and chronic low-grade inflammation all at once. Addressing that with one precursor is a bit like trying to fix a multi-room leak with a single patch. Longevita's formulation takes a different approach: it combines nicotinamide riboside and nicotinamide in the same daily capsule, specifically because the two compounds enter and support the NAD+ system in different, complementary ways. This article explains the biology behind that decision and what the human trial evidence actually shows.

Why NAD+ Support Requires More Than One Lever

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in hundreds of metabolic reactions. It's essential for energy production and cellular repair systems, acting as a substrate for NAD+-dependent enzymes including sirtuins, which regulate metabolism, stress response and longevity; PARPs, which consume NAD+ to repair damaged genetic material; and CD38, an immune enzyme that degrades NAD+ and drives its age-related depletion (Covarrubias et al., 2020).

The challenge every longevity formulation has to solve is that this system doesn't hold steady with age. Ageing is accompanied by a progressive decline in tissue and cellular NAD+ levels, which is causally linked to multiple age-related conditions including neurodegeneration, sarcopenia, metabolic disease and frailty (Fang et al., 2017). We've explored this decline and the specific role of the CD38 enzyme and inflammaging in our article on why NAD+ falls with age and the role of CD38 and inflammaging.

Because NAD+ itself can't be reliably absorbed intact through oral intake, the practical strategy is to supply precursor molecules the body already knows how to convert into NAD+ through its own salvage pathway. Longevita provides NAD+ precursors nicotinamide riboside and niacinamide to boost healthy NAD+ availability, which helps maintain cellular energy metabolism and repair-related enzyme function, according to the brand's own published science. This article answers the question: why both, rather than just one?

What Nicotinamide Riboside Contributes

Nicotinamide riboside chloride is the chloride salt of nicotinamide riboside, a vitamin B3 analogue comprising nicotinamide bound to a ribose moiety. Once ingested, NR enters cells and is phosphorylated by nicotinamide riboside kinases (NRK1/2) into nicotinamide mononucleotide (NMN), which is then converted into NAD+, a route that bypasses the rate-limiting NAMPT step of the salvage pathway that other precursors must pass through (Covarrubias et al., 2020). The European Food Safety Authority has confirmed that ingested NR chloride reliably yields nicotinamide, and ultimately NAD+, in humans.

This bypass matters because NAMPT, the enzyme that normally gates the salvage pathway, tends to become less efficient with age and inflammation, at precisely the same time that NAD+-consuming enzymes like CD38 are becoming more active (Covarrubias et al., 2020; Fang et al., 2017). NR offers a more direct route to raising NAD+ availability even as that bottleneck develops.

The Human Trial Evidence for NR

In an 8-week randomised, double-blind, placebo-controlled trial, healthy overweight adults given 100 to 1,000 mg per day of NR chloride showed dose-dependent increases in whole-blood NAD+; the highest dose raised levels by roughly 142% over baseline within two weeks, sustained for the remainder of the study, with no flushing or major adverse events (Conze et al., 2019).

The effects in older adults go beyond simply raising a number. In a crossover study, twelve men aged 70 to 80 took a gram of NR chloride daily for three weeks. Muscle NAD+-related metabolites rose, RNA profiling showed a shift away from inflammatory and mitochondrial stress signalling, and circulating inflammatory markers  IL-6, IL-2 and TNF-α fell significantly on NR (Elhassan et al., 2019). At the mechanistic level, raising NAD+ through NR activates sirtuins including SIRT1 and SIRT3, enzymes that deacetylate proteins involved in mitochondrial biogenesis and oxidative metabolism (Cantó et al., 2012).

NR's contribution to a daily protocol, in short, is speed and mechanistic directness: a NAMPT-independent route that reliably raises circulating NAD+ and produces a measurable anti-inflammatory signature in ageing tissue.

What Nicotinamide Contributes

Nicotinamide (niacinamide) takes a different, longer-established road into the same system. Along with nicotinic acid, it feeds into NAD+ and NADP+ synthesis through the de novo, Preiss–Handler and salvage pathways, together forming what researchers describe as the broader "vitamin B3 metabolome" (Makarov et al., 2019). By sustaining cellular NAD+ pools, nicotinamide supports mitochondrial energy metabolism and ATP production, fuels DNA repair through PARP enzymes, regulates epigenetic and stress-response programmes via sirtuins, and maintains redox balance through NADPH-dependent antioxidant systems (Covarrubias et al., 2021).

The Human Trial Evidence for Nicotinamide

Nicotinamide's strongest evidence base sits in DNA repair. PARP enzymes rely on NAD+ as their sole substrate to fix DNA strand breaks. When niacin is restricted in human skin cells, NAD+ falls, PARP activation after UV-like damage is blunted, and background DNA damage increases; restoring niacin reverses all of it (Benavente et al., 2012). In human keratinocytes, pharmacological nicotinamide prevents UV-induced ATP depletion and accelerates removal of DNA photolesions, meaning fewer persistent lesions after sun exposure (Surjana et al., 2013).

Nicotinamide also has direct evidence in ageing human muscle. A trial in older inactive men found that short-term nicotinic acid intake increased skeletal muscle mitochondrial respiration and boosted key components of the electron transport chain, directly increasing the muscle's capacity to produce ATP (Deane et al., 2024). And in a human progeroid disorder (Cockayne syndrome), nicotinamide supplementation shifted patient cells away from a highly inflamed state by normalising inflammatory and autophagy-related gene expression (Chikhaoui et al., 2024).

Nicotinamide's contribution to a daily protocol, in short, is breadth and durability: it reinforces the DNA repair, redox balance and anti-inflammatory pathways that depend on a sustained NAD+ pool, backed by decades of established safety data.

Why the Combination Matters More Than Either Compound Alone

Laid side by side, the case for pairing NR and nicotinamide comes down to three points.

They enter the NAD+ pathway differently. NR is phosphorylated by NRK1/2 into NMN before conversion to NAD+, bypassing the NAMPT-dependent step. Nicotinamide re-enters the salvage pathway through NAMPT itself, alongside broader contributions via the Preiss–Handler and de novo routes (Makarov et al., 2019). A formula relying on just one of these is betting that a single enzymatic entry point is sufficient,  even though both routes are active in the body simultaneously and respond differently to age-related changes in enzyme efficiency.

Their strongest evidence covers different outcomes. NR's trial data is strongest for raising whole-blood NAD+ quickly and for reducing inflammatory markers in ageing muscle (Conze et al., 2019; Elhassan et al., 2019). Nicotinamide's trial data are strongest for PARP-dependent DNA repair and mitochondrial ATP production in ageing tissue (Benavente et al., 2012; Deane et al., 2024). Neither literature substitutes for the other; they're answering different physiological questions.

Their downstream mechanisms emphasise different systems. NR's biology leans on sirtuin activation and mitochondrial biogenesis (Cantó et al., 2012). Nicotinamide's biology leans more on PARP-driven genomic stability and NADPH-dependent antioxidant defence (Covarrubias et al., 2021). NAD+ decline affects all of these systems concurrently in ageing cells, which is the entire reason a single-precursor formula leaves gaps.

This is the reasoning documented across Longevita's own ingredient science for nicotinamide riboside chloride and nicotinamide: NR is included specifically to boost NAD+ levels and activate sirtuins for DNA repair, while nicotinamide is included to sustain NAD+ pools for mitochondrial energy and antioxidant defence. Together, they cover a wider span of the NAD+-dependent biology than either could alone. We've gone deeper into the specific mechanistic differences between the two compounds in our dedicated comparison, NR vs nicotinamide: why Longevita uses both NAD+ precursors.

How This Fits Into a Daily Protocol, Not an Occasional Boost

The combination only delivers its full value with consistent, daily use, which is the model Longevita is built around. Longevity outcomes come from sustained physiological change over months and years, not a single high-concentration event. That's reflected directly in the repeat-dose clinical data behind both compounds: the NR trial's NAD+ elevation was tracked and maintained across a full eight-week period of continued daily dosing, not a one-time spike (Conze et al., 2019).

Longevita is formulated as a single daily capsule, described on the brand's own site as beginning your journey to healthy ageing with "one daily ritual"  combining 12 evidence-backed ingredients designed to boost NAD+ levels and target cellular ageing across the body. NR and nicotinamide sit at the core of that formulation as the two NAD+ precursors, working alongside polyphenols such as pterostilbene and trans-resveratrol to support AMPK-related pathways, and antioxidants including CoQ10 and lutein to strengthen the body's broader antioxidant network.

That last piece matters for understanding where NAD+ support fits into overall mitochondrial health. Raising NAD+ availability is only part of the picture; what mitochondria do with that energy, and how well they're protected from oxidative stress while doing it, is a separate but connected question. We cover this in our article on CoQ10 and its role in supporting cellular energy and healthy ageing, which works alongside NR and nicotinamide within Longevita's formulation to support ATP production and reduce oxidative stress system-wide, rather than as a standalone ingredient.

Safety Profile

Both compounds carry a well-documented safety record at the doses used in NAD+ research. The 8-week NR chloride trial reported no flushing and no major adverse events even at 1,000 mg/day, with blood lipids and one-carbon metabolism remaining unchanged throughout (Conze et al., 2019). Nicotinamide, distinct from nicotinic acid, has decades of established use as a well-tolerated form of vitamin B3, without the flushing response commonly associated with high-dose niacin. Longevita's formulation is doctor-formulated, third-party tested, and manufactured in a GMP-certified, USFDA-registered facility in the UK.

The Bottom Line

NR and nicotinamide aren't interchangeable ingredients competing for the same slot in a formula; they're two distinct, well-documented entry points into a NAD+ system that governs mitochondrial energy, DNA repair, epigenetic stability, antioxidant defence and inflammaging simultaneously. NR offers a fast, NAMPT-independent route to raising NAD+ with a compelling anti-inflammatory signature in ageing muscle. Nicotinamide offers deeper evidence in PARP-driven DNA repair and mitochondrial ATP production, backed by decades of safety data.

Formulating with only one of these means leaving the pathways the other compound supports comparatively unaddressed. That's the reasoning behind why Longevita includes both, delivered daily, rather than betting an entire NAD+ strategy on a single molecule.

Precision-calibrated cellular renewal isn't built on one molecular level;  it's engineered through the convergence of complementary NAD+ pathways, delivered with daily consistency. Explore the dual-precursor, doctor-formulated protocol behind Longevita.

FAQs

1. Why does Longevita use both NR and nicotinamide instead of just one?

NR and nicotinamide enter the NAD+ synthesis pathway through different enzymatic routes and have the strongest clinical evidence for different outcomes: NR for rapidly raising whole-blood NAD+ and reducing inflammatory markers, nicotinamide for PARP-dependent DNA repair and mitochondrial ATP production. Combining them addresses a wider range of NAD+-dependent biology than either precursor alone.

2. Is taking NR and nicotinamide together safe?

Yes, based on the available human trial data. Clinical trials on NR chloride at doses up to 1,000 mg/day reported no major adverse events and stable blood lipids, and nicotinamide has decades of established safety as a well-tolerated form of vitamin B3. The two compounds work through complementary, non-duplicating points in the NAD+ pathway.

3. How quickly do NR and nicotinamide raise NAD+ levels?

Clinical trial data on nicotinamide riboside shows measurable increases in whole-blood NAD+ within two weeks of daily supplementation, with levels sustained through continued daily dosing across an eight-week study period.

4. Does Longevita's formula include anything besides NAD+ precursors?

Yes. Alongside nicotinamide riboside and nicotinamide, Longevita's formulation includes polyphenols such as pterostilbene and trans-resveratrol for AMPK-related pathway support, along with antioxidants including CoQ10 and lutein, combined across 12 evidence-backed ingredients in a single daily capsule.

References

Benavente, C.A. et al. (2012) 'Cellular NAD Replenishment Confers Marked Neuroprotection against UV-Induced Cell Death', PLOS ONE, 7(7), e42276.

Cantó, C. et al. (2012) 'The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity', Cell Metabolism, 15(6), pp. 838–847.

Chikhaoui, A. et al. (2024) 'Nicotinamide ameliorates the inflammatory and senescent phenotype in Cockayne syndrome cells'.

Conze, D., Brenner, C. & Kruger, C.L. (2019) 'Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomised, double-blind, placebo-controlled clinical trial of healthy overweight adults', Scientific Reports, 9, Article 9772.

Covarrubias, A.J., Perrone, R., Grozio, A. & Verdin, E. (2020/2021) 'NAD+ metabolism and its roles in cellular processes during ageing', Nature Reviews Molecular Cell Biology, 22, pp. 119–141.

Deane, C.S. et al. (2024) 'Nicotinic acid supplementation and skeletal muscle mitochondrial respiration in older men'.

Elhassan, Y.S. et al. (2019) 'Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures', Cell Reports, 28(7), pp. 1717–1728.

Fang, E.F. et al. (2017) 'NAD+ in Ageing: Molecular Mechanisms and Translational Implications', Trends in Molecular Medicine, 23(10), pp. 899–916.

Makarov, M.V. et al. (2019) 'The chemistry of the vitamin B3 metabolome', Biochemical Society Transactions, 47(1), pp. 131–147.

Surjana, D., Halliday, G.M. & Damian, D.L. (2013) 'Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin', Carcinogenesis, 34(5), pp. 1144–1149.